Disc Medicine, Inc. (IRON) · Sep 10, 2026 · Other events

Disc Medicine’s DISC-3405 cuts PV phlebotomy, but Phase 2 proof remains early

Above the bar — Phlebotomy fell from 4.0 to 0.6 events; 61.5% remained phlebotomy-free

DISC-3405 kept hematocrit below 45% and cut phlebotomy sharply in early PV data, though only 13 patients reached 26 weeks.

The timing was expected; the magnitude of the clinical signal is the new information. Disc had already guided to initial RESTORE-PV data in the third quarter of 2026, so this is not a surprise event on timing. The market was looking for evidence that iron restriction could control hematocrit while reducing patients’ dependence on blood removal—not merely pharmacodynamic proof that DISC-3405 raises hepcidin.

MetricRESTORE-PV resultComparison
Mean phlebotomy events over 26 weeks0.64.0 during the 26-week baseline period (RESTORE-PV results)
Participants phlebotomy-free through 26 weeks61.5%Post-baseline (RESTORE-PV results)
Participants phlebotomy-free during first maintenance period77.8%Weeks 12–32; n=9 (RESTORE-PV results)
Mean hematocritBelow 45%Maintained through week 26 (Other Events)
Cohort A completing 26 weeks13 patientsOf 20 dosed (Trial design and data cut)

The efficacy readout clears the practical bar investors were watching. Among the 13 Cohort A patients who completed 26 weeks, mean phlebotomy events dropped from 4.0 to 0.6, while 61.5% stayed completely phlebotomy-free. The filing also reports that mean hematocrit remained stably below 45% through week 26. 〔0〕 〔1〕

The result is meaningful because it connects mechanism to patient-relevant outcomes. The filing shows dose-proportional pharmacokinetics, increased hepcidin, lower serum iron, controlled hematocrit, and fewer phlebotomies rather than stopping at laboratory changes. 〔2〕 That combination is better than a merely in-line mechanistic update and supports continued development toward a pivotal study.

The main limitation is that this is an encouraging early signal, not a definitive Phase 2 verdict. Efficacy is reported for only Cohort A, with 13 patients completing 26 weeks, and the study is open-label with no control arm. Cohort B contributes baseline and safety information but not yet a comparable efficacy dataset. The safety profile was generally acceptable, with mild, self-limited injection-site reactions reported. 〔3〕

Net: better than the standing expectation for an initial data release, while the next update must show durability and broader confirmation. The current evidence supports a positive clinical read, but the valuation-relevant question shifts to whether hematocrit control and phlebotomy reduction persist across more patients, including the every-four-week cohort. Disc plans another RESTORE-PV update and initial sickle-cell data by the end of 2026.

What to watch next

RESTORE-PV update and SCD Phase 1b data by end-2026

Original filing on SEC EDGAR

More Disc Medicine, Inc. news

Disc Medicine’s DISC-3405 cuts PV phlebotomy, but Phase 2 proof remains early | IRON Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.